razoxane has been researched along with prednisone in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Das, S; Freedman, LS; Garrett, MJ; Smith, JD | 1 |
Vogel, CL | 1 |
Ben-Yehuda, D; Lossos, IS | 1 |
Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L | 1 |
Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
1 review(s) available for razoxane and prednisone
Article | Year |
---|---|
Management of Kaposi's sarcoma. Chemotherapy I.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Carmustine; Dactinomycin; Humans; Immunosuppressive Agents; Prednisone; Razoxane; Sarcoma, Kaposi; Vinca Alkaloids | 1981 |
1 trial(s) available for razoxane and prednisone
Article | Year |
---|---|
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine | 2010 |
3 other study(ies) available for razoxane and prednisone
Article | Year |
---|---|
Long term experience with combination chemotherapy in advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Agents; Bleomycin; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Leukemia; Lomustine; Male; Mechlorethamine; Middle Aged; Mutagens; Neoplasms, Multiple Primary; Oxymetholone; Prednisone; Pregnancy; Procarbazine; Razoxane; Teratogens; Vinblastine; Vincristine | 1977 |
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Necrosis; Prednisone; Razoxane; Skin; Vincristine | 1999 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |